RANKL/OPG in primary cultures of osteoblasts from post-menopausal women. Differences between osteoporotic hip fractures and osteoarthritis

Journal of Steroid Biochemistry and Molecular Biology

Volumn 113, Issue 1-2, 2009, Pages 46-51

  Giner, Mercè ^a   Rios, Ma José ^b   Montoya, Ma José ^b   Vázquez, Ma Angeles ^b   Naji, Latifa ^a   Pérez Cano, Ramón ^a,b  

^a HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

1,25 Dihydroxyvitamin D; 17 Beta estradiol; Human osteoblast culture; OPG RANKL; Osteoporosis

Indexed keywords

CALCITRIOL; ESTRADIOL; OSTEOCLAST DIFFERENTIATION FACTOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

AGED; ARTICLE; CELL CULTURE; CONTROLLED STUDY; FEMALE; HIP FRACTURE; HISTOCHEMISTRY; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOARTHRITIS; OSTEOBLAST; OSTEOPOROSIS; POSTMENOPAUSE; PROTEIN EXPRESSION;

AGED; AGED, 80 AND OVER; CELLS, CULTURED; ESTRADIOL; FEMALE; GENE EXPRESSION REGULATION; HIP FRACTURES; HUMANS; OSTEOARTHRITIS; OSTEOBLASTS; OSTEOPOROSIS; OSTEOPROTEGERIN; POSTMENOPAUSE; RANK LIGAND; RNA, MESSENGER; VITAMIN D;

EID: 59849084985     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2008.11.005     Document Type: Article

References (35)

1. Pogrund H., Rutenberg M., Makin M., Robin G., Menczel J., and Steinberg R. Osteoarthritis of the hip joint and osteoporosis: a radiological study in a random population sample in Jerusalem. Clin. Orthop. Relat. Res. 164 (1982) 130-135
2. Arden N.K., Nevitt M.C., Lane N.E., Gore L.R., Hochberg M.C., Scott J.C., Pressman A.R., and Cummings S.R. Osteoarthritis and risk of falls, rates of bone loss, and osteoporotic fractures, Study of Osteoporotic Fractures Research Group. Arthritis Rheum. 42 (1999) 1378-1385
3. Jordan G.R., Loveridge N., Power J., Clarke M.T., and Reeve J. Increased cancellous bone in the femoral neck of patients with coxarthrosis (hip osteoarthritis): a positive remodeling imbalance favoring bone formation. Osteoporosis Int. 14 (2003) 160-165
4. Jordan G.R., Loveridge N., Bell K.L., Power J., Dickson G.R., Vedi S., Rushton N., Clarke M.T., and Reeve J. Increased femoral neck cancellous bone and connectivity in coxarthrosis (hip osteoarthritis). Bone 32 (2003) 86-95
5. Logar D.B., Komadina R., Prezelj J., Ostanek B., Trost Z., and Marc J. Expression of bone resorption genes in osteoarthritis and in osteoporosis. J. Bone Miner. Metab. 25 (2007) 219-225
6. Fuller K., Wong B., Fox S., Choi Y., and Chambers T.J. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188 (1998) 997-1001
7. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
8. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., Nguyen H.Q., Wooden S., Bennett L., Boone T., Shimamoto G., DeRose M., Elliott R., Colombero A., Tan H.L., Trail G., Sullivan J., Davy E., Bucay N., Renshaw-Gegg L., Hughes T.M., Hill D., Pattison W., Campbell P., Sander S., Van G., Tarpley J., Derby P., Lee R., and Boyle W.J. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
9. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Spelsberg T.C., and Riggs B.L. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 (1999) 4367-4370
10. Vázquez M.A., Montoya M.J., Gómez de Tejada M.J., Moruno R., Carrillo A., Guerrero J.M., and Pérez-Cano R. Niveles séricos de osteoprotegerina en mujeres sanas y osteoporóticas. REEMO 12 (2003) 63-67
11. Abdallah B.M., Stilgren L.S., Nissen N., Kassem M., Jorgensen H.R., and Abrahamsen B. Increased RANKL/OPG mRNA ratio in iliac bone biopsies from women with hip fractures. Calcified Tissue Int. 76 (2005) 90-97
12. Viereck V., Grundker C., Blaschke S., Siggelkow H., Emons G., and Hofbauer L.C. Phytoestrogen genistein stimulates the production of osteoprotegerin by human trabecular osteoblasts. J. Cell Biochem. 84 (2002) 725-735
13. Cheung J., Mak Y.T., Papaioannou S., Evans B.A., Fogelman I., and Hampson G. Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. J. Endocrinol. 177 (2003) 423-433
14. Saika M., Inoue D., Kido S., and Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology 142 (2001) 2205-2212
15. Taranta A., Brama M., Teti A., De luca V., Scandurra R., Spera G., Agnusdei D., Termine J.D., and Migliaccio S. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 30 (2002) 368-376
16. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20 (1999) 345-357
17. Horwood N.J., Elliott J., Martin T.J., and Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139 (1998) 4743-4746
18. Zhang D., Yang Y.Q., Li X.T., and Fu M.K. The expression of osteoprotegerin and the receptor activator of nuclear factor kappa B ligand in human periodontal ligament cells cultured with and without 1alpha,25-dihydroxyvitamin D3. Arch. Oral Biol. 49 (2004) 71-76
19. Hofbauer L.C., Dunstan C.R., Spelsberg T.C., Riggs B.L., and Khosla S. Osteoprotegerin production by human osteoblast lineage cells is stimulated by vitamin D, bone morphogenetic protein-2, and cytokines. Biochem. Biophys. Res. Commun. 250 (1998) 776-781
20. Perinpanayagam H., Zaharias R., Stanford C., Brand R., Keller J., and Schneider G. Early cell adhesion events differ between osteoporotic and non-osteoporotic osteoblasts. J. Orthop. Res. 19 (2001) 993-1000
21. Browner W.S., Lui L.Y., and Cummings S.R. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J. Clin. Endocrinol. Metab. 86 (2001) 631-637
22. Tsangari H., Findlay D.M., Kuliwaba J.S., Atkins G.J., and Fazzalari N.L. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck. Bone 35 (2004) 334-342
23. Fazzalari N.L., Kuliwaba J.S., Atkins G.J., Forwood M.R., and Findlay D.M. The ratio of messenger RNA levels of receptor activator of nuclear factor kappaB ligand to osteoprotegerin correlates with bone remodeling indices in normal human cancellous bone but not in osteoarthritis. J. Bone Miner. Res. 16 (2001) 1015-1027
24. Baldock P.A., Thomas G.P., Hodge J.M., Baker S.U., Dressel U., O'Loughlin P.D., Nicholson G.C., Briffa K.H., Eisman J.A., and Gardiner E.M. Vitamin D action and regulation of bone remodeling: suppression of osteoclastogenesis by the mature osteoblast. J. Bone Miner. Res. 21 (2006) 1618-1626
25. Atkins G.J., Anderson P.H., Findlay D.M., Welldon K.J., Vincent C., Zannettino A.C., O'Loughlin P.D., and Morris H.A. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha,25-dihydroxyvitamin D3. Bone 40 (2007) 1517-1528
26. Spelsberg T.C., Subramaniam M., Riggs B.L., and Khosla S. The actions and interactions of sex steroids and growth factors/cytokines on the skeleton. Mol. Endocrinol. 13 (1999) 819-828
27. Bord S., Ireland D.C., Beavan S.R., and Compston J.E. The effects of estrogen on osteoprotegerin, RANKL, and estrogen receptor expression in human osteoblasts. Bone 32 (2003) 136-141
28. Lindberg M.K., Alatalo S.L., Halleen J.M., Mohan S., Gustafsson J.A., and Ohlsson C. Estrogen receptor specificity in the regulation of the skeleton in female mice. J. Endocrinol. 171 (2001) 229-236
29. Nagai M., and Sato N. Reciprocal gene expression of osteoclastogenesis inhibitory factor and osteoclast differentiation factor regulates osteoclast formation. Biochem. Biophys. Res. Commun. 257 (1999) 719-723
30. Thomas G.P., Baker S.U., Eisman J.A., and Gardiner E.M. Changing RANKL/OPG mRNA expression in differentiating murine primary osteoblasts. J. Endocrinol. 170 (2001) 451-460
31. Murakami T., Yamamoto M., Ono K., Nishikawa M., Nagata N., Motoyoshi K., and Akatsu T. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells. Biochem. Biophys. Res. Commun. 252 (1998) 747-752
32. Hopwood B., Gronthos S., Kuliwaba J.S., Robey P.G., Findlay D.M., and Fazzalari N.L. Identification of differentially expressed genes between osteoarthritic and normal trabecular bone from the intertrochanteric region of the proximal femur using cDNA microarray analysis. Bone 36 (2005) 635-644
33. Chen F.P., Lee N., Wang K.C., Soong Y.K., and Huang K.E. Effect of estrogen and 1alpha,25(OH)2-vitamin D3 on the activity and growth of human primary osteoblast-like cells in vitro. Fertil. Steril. 77 (2002) 1038-1043
34. Bellido T., Girasole G., Passeri G., Yu X.P., Mocharla H., Jilka R.L., Notides A., and Manolagas S.C. Demonstration of estrogen and vitamin D receptors in bone marrow-derived stromal cells: up-regulation of the estrogen receptor by 1,25-dihydroxyvitamin-D3. Endocrinology 133 (1993) 553-562
35. Vertino A.M., Bula C.M., Chen J.R., Almeida M., Han L., Bellido T., Kousteni S., Norman A.W., and Manolagas S.C. Nongenotropic, anti-apoptotic signaling of 1alpha,25(OH)2-vitamin D3 and analogs through the ligand binding domain of the vitamin D receptor in osteoblasts and osteocytes. Mediation by Src, phosphatidylinositol 3-, and JNK kinases. J. Biol. Chem. 280 (2005) 14130-14137